| New Frontiers for Fairer Breast Cancer Care in a Globalized World | Didier VERHOEVEN, Claudia ALLEMANI, Cary KAUFMAN, Sabine SIESLING, Manuela JOORE, Etienne BRAIN, Mauricio MAGALHÃES COSTA | 86–94 |
| Breast Cancer Perception Scale: Psychometric Development Study | Derya ADIBELLİ, İlknur ÖZKAN, Seçil TAYLAN | 95–102 |
| Cytological Evaluation of Pathological Male Breast Lesions | Krishnendu MONDAL, Rupali MANDAL | 103–111 |
| Angiotensin-Converting Enzyme 2 Gene Expression in Breast Tissue | Sammy AL-BENNA | 112–115 |
| Validity and Reliability of the Turkish Version of the Breast Cancer Screening Beliefs Scale | Aslı SİS ÇELİK, Nihan TÜRKOĞLU | 116–122 |
| Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study | Abdullah SAKİN, Nurgül YAŞAR, Çağlayan GEREDELİ, Şener CİHAN, Serdar ARICI, Ruhper ÇEKİN, Şaban SEÇMELER, Muhammed Mustafa ATCI, Seval AY, Mahmut GÜMÜŞ, Biray ERTÜRK, Orçun CAN | 123–127 |
| Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy | Hongxia SUN, Hui CHEN, James CRESPO, Guilin TANG, Melissa ROBINSON, Bora LIM, Ayşegül A. ŞAHİN | 128–136 |
| The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey | Neslihan DUZKALE, Olcay KANDEMİR | 137–144 |
| Were We Able to Reduce Cardiac Doses in Breast Cancer Radiotherapy Over Time? | Pelin ALTINOK, Nuran BEŞE, Latif KORKMAZ, Ayse ALTINOK | 145–149 |
| Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study | Gary DONOVITZ, Mandy COTTEN | 150–156 |
| Evaluation of Factors Related to Postoperative Complications in Patients Who Underwent Reduction Mammoplasty | Gaye TOPLU, Merdan SERİN, Dinçer ALTINEL | 157–164 |
| A Practical, Clinical User-Friendly Format for Breast Ultrasound Report |